Tag Archives: nanomedicine

Meet us at EuroNanoForum 2017

Iraida Loinaz, coordinator of the PneunoNP project, attends the EuroNanoForum 2017 conference.

EuroNanoForum 2017 is an international event that focus on how nano and materials technologies can strengthen competitiveness across all European industries. The event takes place in Malta from 21th and 23th June 2017.

Nanotechnology is expected to gain importance in the near future in many industries. For example, nanomedicine could solve numerous healthcare challenges especially in the field of drug-delivery. However, from the pharmaceutical point of view, there is insufficient clinical data that allows the assessment of the role of nanotechnology in the potential of these products.

It is time to push those promising developments to the clinical stage. Iraida Loinaz’s talk will show real examples on how is possible to translate a lab scale protocol, into a robust GMP manufacturing process, and those key aspects to take into account to reduce the time of development.


Iraida Loinaz, coordinator of PneunoNP project, is the Health business development Manager of IK4-Cidetec. In the last years Dr. Loinaz’s group has been specialized in translational research. They are establishing a pilot plant operating under GMP for the production of nanopharmaceuticals.

“It is my first time attending EuroNanoForum,” Dr Loinaz said. “I really look forward to meeting main stakeholders in the field of nanotechnologies for health and share our experiences in the field.”

Find all the necessary information related to the event on: www.eccmid.org.

EuroNanoForum 2017 logo

__________________________________________________________________
Follow the PneumoNP team from event to event
ENF2017_logo_web-red

Meet us at EuroNanoForum 2017

Iraida Loinaz, coordinator of the PneunoNP project, attends the EuroNanoForum 2017 conference. EuroNanoForum 2017 is an international event that focus ...
Read More
Molecular Imaging Workshop 2017

Call for abstracts for the Molecular Imaging Workshop 2017

The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in ...
Read More
7_ECCMID_Vienna 2017 picture-logo_480x310

Meet us at ECCMID 2017

PneumoNP partners will attend ECCMID 2017 in Vienna, Austria, from 22-25th April 2017. ECCMID is a major event for experts ...
Read More

Imaging data reveals nanomedicines in lungs

An experiment carried out in Spain shows the distribution of an inhaled nanomedicine in rat lungs.

The PneumoNP project aims at developing new inhaled nanotherapeutic formulations to combat lung infection. The novel drug is comprised of an antibiotic carried by a nanoparticle. For this project, Spanish researchers from CIC BiomaGUNE track the location of the therapeutic particles in rat airways.

The use of nanoparticles in formulations is anticipated to lengthen the residence time of the drug in lungs. Indeed, it is expected to slow down and control the release of the active molecules. This prevents rapid metabolism and fast clearance. So, the therapeutic effects are expected to increase. Besides, the delivery by inhalation contributes to diminish undesired toxicological and off-target side effects. The results obtained in imaging experiments are essential to establish the appropriate dosage to be used in therapeutic experiments with infected animals and to predict therapeutic efficacy.

PET image

Positron emission tomography image showing the regional distribution of aerosolized nanocarrier-antibiotic formulation in rat lung.

The researchers have developed labeling methods to incorporate different radionuclides to the nanocarrier and the antibiotic. Thanks to the different physical properties of the radionuclides, they visualize the spatiotemporal distribution of the nanocarrier and the antibiotic separately. To achieve that they also used complementary in vivo imaging modalities.

From imaging experiments, relevant information can be determined quantitatively by using only few experimental animals and extremely refined procedures. The percentage of administered dose that reaches the lungs is important to assess the efficacy of the aerosol delivery method. The researcher looks also for the regional distribution of the antibiotic and the nanocarrier within the lungs. With the spatiotemporal imaging, they evaluated the residence time of the active drug and the nanocarrier in the lungs.

__________________________________________________________________

Read related PneumoNP news

illustration-scientifique-aerosol-v01-01

A step forward towards therapeutic aerosols

A delivery device for a breathable drug has been prototyped to test a new drug formulation. It aims to fight ...
Read More
Action of a M33 peptide on the membrane of a gram-negative bacteria

M33, the new option to fight severe pneumonia

The antimicrobial peptide M33 may be the long-sought substitute to treat difficult lung infections, like multi-drug resistant pneumonia. In 2013, ...
Read More
In vivo antibacterial activity of SET-M33L peptide in skin infection. Example of images of five animals at day 2.

New publication: In vitro and in vivo tests for a novel antibacterial drug candidate

In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate Abstract: A synthetic ...
Read More
PneumoNP concept

Heal pulmonary infections with nanosystems

Fine nanosystems carrying Meropenem and antimicrobial peptides to fight pulmonary infections are ready for in vitro tests. Before 2016 starts, ...
Read More